Patients with rheumatoid arthritis (RA) have an increased mortality and morbidity due to cardiovascular disease and accelerated progression of atherosclerosis. Altered populations of T-lymphocytes are associated with atherosclerosis, and chronic infection with cytomegalovirus (CMV) affects the T-cell-population. Objectives: To study the association between subsets of T-lymphocytes, subclinical atherosclerosis assessed by intima-media thickness (IMT) and antibodies against CMV in patients with RA. Methods: Patients with new-onset RA (n=71), aged ≤60 years at diagnosis, were consecutively included in a study of development of atherosclerosis. Ultrasound measurement of IMT of a. carotis communis was undertaken at inclusion (T0), after five years (T5) and after 11 years (T11) (n=54). At T11, flow-cytometry was undertaken to investigate subsets of T-lymphocytes (CD45+CD3+), where CD4, CD8, CD28, CD56 and CX3CR1 was studied. CX3CR1 is the ligand of fractalkine, an adhesion molecule expressed on activated endothelial cells to attract leukocytes. Serological analysis for CMV was undertaken from samples collected at T0, T5 and T11. Results: The percentage of CD8+T-lymphocytes lacking the co-stimulatory molecule CD28 (CD8+CD28-) was significantly (standardized beta coefficient 0.39, p-value 0.01) associated with IMT at T11 in a linear regression model including T0 variables smoking, systolic blood pressure and cholesterol. No association with IMT was seen for CD4+CD28-T-lymphocytes. CX3CR1 was expressed in 71% of CD8+CD28-T-lymphocytes, compared with 8.2% of CD8+CD28+. The prevalence of immunoglobulin G seropositivity for CMV was 47/70 (67%), 42/66 (57%) and 34/56 (52%) at T0, T5 and T11 respectively. Patients with constantly positive CMV serologies (T0, T5 and T11) had a significantly higher percentage of CD8+CD28-and CD4+CD28-T-lymphocytes. Also the proportion of cells expressing CX3CR1 was in both CD4+ and CD8+ T-lymphocytes associated with constantly positive serologies for CMV.
THU0130 IMPROVEMENT IN MEASURES OF DEPRESSED MOOD AND

ANHEDONIA IN TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDIES OF SIRUKUMAB, A HUMAN ANTI-INTERLEUKIN-6 ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS
Background: Interleukin-6 (IL-6) is one of the known neuroactive-cytokines involved in neuronal plasticity and stress coping and is associated with depression. Depressive symptoms are common in patients with rheumatoid arthritis (RA), a disease characterized by high peripheral IL-6. Previous analysis of a Phase II study 1 showed that sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, can help reduce depressive symptoms in RA patients. Objectives: To further assess and validate the effects of sirukumab on relieving depressive symptoms in RA patients. Methods: We conducted a post-hoc analysis of 2 Phase III, randomized, doubleblind, placebo-controlled trials evaluating efficacy and safety of sirukumab in the treatment of RA. SIRROUND-D enrolled patients with active RA despite disease-modifying anti-rheumatic drugs and having serum C-reactive protein (CRP)≥8mg/L at baseline. SIRROUND-T enrolled patients with active RA despite anti-TNF therapy and having serum CRP≥8mg/L or erythrocyte sedimentation rate≥28mm/h at baseline. Patients using antidepressants were excluded from the analysis. Patients were grouped by presence/absence of prevalent depressed mood and anhedonia (PDMA), based on the self-reported frequencies of these 2 core depressive symptoms in the SF-36, requiring one present at least "most of the time" and the other "some of the time" in the past 4 weeks. A depression score was derived based on the 2 core depressive symptoms of SF-36. Relief of depressive symptoms in patients with PDMA was evaluated by comparing changes in the depression score from baseline to week 8 between the placebo and combined sirukumab groups directly and with adjustment for RA activity as measured by the Disease Activity Score-28 with CRP. Changes in depression score were also analyzed in RA patients who did not have an ACR50 response to sirukumab. The combined effect of anti-IL-6 treatment was estimated using meta-analysis of 2 Phase III, 1 Phase II studies of sirukumab and 1 Phase II study of the anti-IL-6 cytokine antibody siltuximab. Results: At baseline, 19% and 22% of patients were classified as PDMA in the 2 studies, respectively. Sirukumab treatment, compared to placebo, significantly improved depressive symptoms by week 8 among PDMA patients (p=0.022 and 0.046 for the 2 studies, respectively) before adjusting for changes in RA activity. Within the sirukumab group, the reduction in depressive symptoms remained significant after adjusting for changes in RA activity (p<0.0001) and in ACR50 non-responders at week 8 (p<0.0001), while differences in improvements between the sirukumab and placebo group reduced to trends. Meta-analysis of 4 anti-IL-6 studies (1 siltuximab, 3 sirukumab) revealed that anti-IL-6 treatment helps alleviate depressive symptoms even after adjusting for changes in disease activity (Standardized Mean Difference =0.25, p=0.03). Conclusions: Our findings are consistent with previous results from a phase II RA study. Peripheral anti-IL-6 cytokine treatment is associated with improvement in depressive symptoms in RA patients, possibly supporting a role for IL-6 dysfunction in depression. 
Conclusions:
As a results CHD were detected in 5,7 percents of RA patients who are receiving biological agents. Importantly, two third of these patients have
